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Abstract 
Intracranial neoplasia is frequently encountered in dogs. After a presumptive diagnosis of intracranial neoplasia is 
established based on history, clinical signs and advanced imaging characteristics, the decision to treat and which 
treatment to choose must be considered. The objective of this study is to report survival times (ST) for dogs with 
intracranial meningiomas and gliomas treated with surgical resection alone (SRA), to identify potential prognostic 
factors affecting survival, and to compare the results with the available literature. Medical records of 29 dogs with 
histopathologic confirmation of intracranial meningiomas and gliomas treated with SRA were retrospectively 
reviewed. For each dog, signalment, clinical signs, imaging findings, type of surgery, treatment, histological 
evaluation, and ST were obtained. Twenty-nine dogs with a histological diagnosis who survived >7 days after surgery 
were included. There were 15 (52%) meningiomas and 14 (48%) gliomas. All tumors had a rostrotentorial location. 
At the time of the statistical analysis, only two dogs were alive. Median ST for meningiomas was 422 days (mean, 
731 days; range, 10-2735 days). Median ST for gliomas was 66 days (mean, 117 days; range, 10-730 days). Kaplan-
Meier analysis indicated that ST was significantly longer for meningiomas than for gliomas (P<0.05). A negative 
correlation between the presence of a midline shift and ST (P=0.037) and ventricular compression and ST (P=0.038) 
was observed for meningiomas. For gliomas, there were no significant associations between ST and any of the 
variables evaluated. In conclusion, the results of this study suggest that, for dogs that survived >7 days postoperatively, 
SRA might be an appropriate treatment, particularly for meningiomas, when radiation therapy is not readily available. 
Also, the presence of midline shift and ventricular compression might be negative prognostic factors for dogs with 
meningiomas. 
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Introduction 
Intracranial neoplasia is frequently encountered in dogs 
(Song et al., 2013) and represent a major cause of 
morbidity and mortality (Dickinson, 2014). 
Meningiomas are the most commonly reported primary 
intracranial neoplasm in this species, followed by glial 
tumors, including astrocytomas, oligodendrogliomas, 
and oligoastrocytomas (Snyder et al., 2006; Sessums 
and Mariani, 2009; Song et al., 2013). After a 
presumptive diagnosis of intracranial neoplasia is 
established based on history, clinical signs and 
advanced imaging characteristics, the decision to treat 
and which treatment to choose must be considered. The 
therapeutic modalities most commonly available for 
veterinary patients with intracranial neoplasia include 
palliative care, surgery, chemotherapy and radiation 
therapy, all of which can be used either alone or in 
combination (Dickinson, 2014). Definitive diagnosis of 
intracranial tumors is based on histopathologic 
examination, (Dickinson, 2014) typically following the 
World Health Organization (WHO) classification 
system published in 2007 (Louis et al., 2007). 
Palliative care for intracranial tumors often involves 
glucocorticoids targeting peritumoral edema together 
with antiepileptic drugs to control seizures, (Dickinson, 
2014) which is the most common presenting complaint 
for intracranial tumors in dogs (Bagley et al., 1999; 
Snyder et al., 2006).  
Mean survival time (ST) reported for dogs with 
rostrotentorial meningiomas that received only 
palliative treatment ranged from 54 to 195 days, (Turrel 
et al., 1984; Foster et al., 1988; Bilderback et al., 2006) 
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whereas a median ST of 45 days was reported for 
gliomas (Adams et al., 2005).  
Efficacy of surgical cytoreduction of intracranial 
tumors is highly operator and equipment dependent 
(Dickinson, 2014). Most published information is 
related to more easily accessible canine and feline 
meningiomas, with only anecdotal data for other tumor 
types such as gliomas (Dickinson, 2014). Surgical 
excision alone for canine meningiomas resulted in 
median ST of 180-210 days (Kostolich and Dulisch, 
1987; Niebauer and Dayrell-Hart, 1991; Axlund et al., 
2002; Bilderback et al., 2006; Rossmeisl, 2014). 
Neurosurgical treatment using devices such as 
intracranial endoscopy or ultrasonic surgical aspirator, 
which either improve intraoperative visualization or 
facilitate tumor excision, have been associated with 
longer median ST after surgical resection for 
intracranial meningiomas, with ST ranging from 1260 
to 2100 days. (Greco et al., 2006; Klopp and Rao, 2009; 
Rossmeisl, 2014).  
Currently, no meaningful conclusions can be made 
from published data relating to surgery of intraaxial 
tumors (Dickinson, 2014) and, to the best of the 
authors’ knowledge, a retrospective or prospective 
paper looking for ST for gliomas treated with surgical 
resection alone (SRA) has not been previously 
reported.  
There is little information available about the efficacy 
of chemotherapeutic agents for canine intracranial 
neoplasia. Most data relate to the use of nitrosurea-
based alkylating agents, such as lomustine (CCNU) and 
carmustine, or the ribunucleotide reductase inhibitor 
hydroxyurea (Dickinson, 2014). Anecdotal published 
data show apparent survival benefits and occasional 
responses with survival of many months in some cases 
(Jung et al., 2006; Tamura et al., 2007).  
However, a large retrospective study suggested no 
benefit from lomustine chemotherapy compared to 
palliative care (93 days versus 60 days) for brain 
masses diagnosed via computed tomography and 
without a histologic diagnosis (Van Meervenne and 
Verhoeven, 2014). 
Radiation therapy has become a mainstay of treatment 
for intracranial neoplasia in both human and veterinary 
patients, either as a primary or adjunctive treatment 
(Dickinson, 2014). Radiotherapy has demonstrated to 
improve ST in presumptive and confirmed 
meningiomas, with ST ranging from 240 to 577 days 
(Turrel et al., 1984; Evans et al., 1993; Axlund et al., 
2002; Bley et al., 2005; Griffin et al., 2014; Rossmeisl, 
2014). Radiation therapy has been reported to be 
beneficial when compared to SRA for the treatment of 
meningiomas (Axlund et al., 2002).  
A study including 12 dogs with gliomas treated with 
radiotherapy only, showed a median ST of 255 days 
(Adams et al., 2005). In this same study, the 
combination of surgery and radiotherapy increased the 
median ST to 300 days (Adams et al., 2005). A large 
prospective study analyzing the outcome, ST, and 
complications of the different treatment modalities in 
veterinary medicine is lacking. Consequently, the 
information necessary to choose a particular treatment 
is mainly based on published clinical studies with a 
limited number of cases with variable treatment 
modalities and follow-up, and the personal experience 
of the neurologist/neurosurgeon (Dickinson, 2014).  
Until a large prospective study is designed, conducted 
and published, our aim was to report the long-term 
survival in a cohort of dogs with primary brain tumors 
(meningiomas and gliomas), where standard surgical 
resection was the main treatment modality due to the 
limited availability of radiotherapy, and to compare our 
results with previously published studies.  
We also aimed to assess potential prognostic factors 
pertaining to signalment, magnetic resonance imaging 
(MRI) characteristics or type of tumor associated with 
ST. We hypothesized that ST for meningiomas treated 
with SRA would be longer than previously reported and 
that ST for gliomas following SRA would be longer 
than the ST reported with palliative care across 
previous publications.  
We also hypothesized that the tumor type and some 
specific MRI characteristics, such as the presence of a 
midline shift, peritumoral edema and ventricular 
compression, would have a negative influence on ST.  
Materials and Methods 
Case selection criteria 
Medical records of dogs examined at our hospital from 
April 2002 to December 2013 were retrospectively 
reviewed. All dogs with a histopathologic diagnosis of 
primary intracranial tumor following surgical resection 
were included.  
Medical records review 
Information obtained from the medical records 
included signalment, type and duration of clinical signs, 
tumor location, MRI findings, type of surgery, duration 
of hospitalization, WHO histopathological 
classification, date of recurrence of clinical signs, and 
date and cause of death. If not available in the medical 
records, referring veterinarians and clients were 
contacted by telephone in order to obtain follow-up 
information.  
Procedures and follow-up 
For each dog, hematology, serum biochemistry profile, 
and systemic tumor staging (including 3-view thoracic 
radiographs and abdominal ultrasound) were 
performed to rule out potential underlying or 
concurrent diseases in preparation for surgery. 
Additional ancillary testing was performed as 
indicated.  
For all dogs, a tentative diagnosis of intracranial 
neoplasia was obtained following 0.25 T MRI of the 
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brain (Esaote VetMR Grande, Genoa, Italy) and 
cerebrospinal fluid analysis, both performed under 
general anesthesia.  
A second year neurology resident and a board-certified 
neurologist examined all MR images. For each MRI 
study, tumor type (suspected meningioma versus 
glioma), neuroanatomical location (frontal, parietal, 
temporal), and size of the presumptive brain tumor, as 
well as any secondary changes observed, including the 
presence of a midline shift, peritumoral edema and 
compression of the ventricular system, were recorded. 
The percentage of midline shift was calculated on 
transverse T2-weighted (T2W) fast spin echo images. 
The midline shift was measured as the distance of 
maximum shift from the midline using commercial 
software (Osirix version 4.1.2 DICOM viewer, Pixmeo 
SARL, Bernex, Switzerland) as previously reported 
(Beltran et al., 2014).  
This value was multiplied by 100 and divided by the 
distance from the midline to the convexity surface at 
the same level to calculate the percentage of midline 
shift (Beltran et al., 2014). Peritumoral edema was 
classified as present or absent based on T2W images. If 
present, it was graded as peritumoral if it extended ≤10 
mm beyond the tumor margin on T2W images or as 
diffuse if it extended for >10 mm beyond the tumor 
margin (Sturges et al., 2008).  
Ventricular system compression was evaluated in 
dorsal T1 post contrast images at the level of corpus 
callosum. If there were any abnormality in the 
symmetry, location or size of the ventricles that was 
attributed to direct tumor compression or surrounding 
edema, it was classified as present. If there were no 
abnormality it was classified as absent (Fig. 1). 
Animals were anesthetized for surgery using standard 
hospital protocols. Preanesthetic medications included 
a combination of methadone (0.2-0.4 mg/kg SC/IM, 
Metasedin, Laboratorio Esteve) and acepromazine 
(0.05-0.1mg/kg SC/IM, Equipromacina, Fatro Iberica 
SA). Anesthesia was induced with thiopental (3.0–6.6 
mg/kg, IV, Tiobarbital, Braun) or propofol (4.0–6.0 
mg/kg, IV, Propofol Hospira, Hospira SL) and 
diazepam (0.5 mg/kg IV, Valium, Roche Farma SA) 
and maintained with isoflurane and oxygen (1–2% 
Isoflo, Laboratorio Esteve). All animals received 
perioperative antibiotics (cefazolin, 25 mg/kg, IV, 
every 90 min, Cefazolin Normon, Laboratorios 
Normon SA). 
Two board-certified neurologists performed all surgical 
resections using magnifying loupes and a non-vibrating 
surgical aspirator (Ferguson suction tube, Instrumevet, 
Barcelona, Spain). Surgical approaches and operative 
techniques were performed according to the nature and 
location of the lesion in order to remove the maximal 
volume of tumor observed macroscopically.  
 
 
Fig. 1. T1W post contrast dorsal images at the level of corpus 
callosum. (A): Ventricular compression considered as 
present. (B): Ventricular compression considered as absent. 
 
Once the tumor was located, surgical resection was 
performed as follows: for meningiomas, once a clear 
dissection plane was identified, blunt separation and 
removal of the macroscopic neoplastic tissue was 
achieved with nerve hooks, flat curettes, and bipolar 
cautery.  
For gliomas, since no clear dissection plane was 
evident, a biopsy was obtained using curettes and the 
remaining tumor was removed using a non-vibrating 
surgical aspirator (Ferguson suction tube, Instrumevet, 
Barcelona, Spain) until removal was considered 
macroscopically complete. Hemorrhage was controlled 
via bipolar electrocautery and application of hemostatic 
sponges, when appropriate. Intraoperative mannitol 
was administered prior to dural opening when advanced 
imaging suggested increased intracranial pressure. The 
dura mater was not sutured but hemostatic sponges 
were placed tightly over the craniectomy defect. The 
bone flap was only replaced in dogs that underwent 
transfrontal craniotomy. Soft tissues were closed 
routinely.  
While in recovery, dogs were positioned with the head 
above the level of the heart until alert and responsive, 
and were closely monitored for seizure activity, 
decreased mentation, or hypoventilation.  
For the histopathological study, a biopsy sample was 
obtained during the surgical procedure and fixed in 
10% formalin. A board-certified pathologist evaluated 
all tumors. 
Animals were recovered in the intensive care unit for 
administration of supportive care, broad-spectrum 
antibiotics, and opioid analgesia (methadone at 0.2-0.4 
mg/kg SC (Metasedin, Laboratorio Esteve), or fentanyl 
continuous rate infusion at 3–6 μg/kg/h IV (Fentanest, 
Kern pharma) until discharge. After surgery, treatment 
included oral anticonvulsants and glucocorticoids for 
epileptic seizure control and peritumoral edema 
reduction, respectively. Regular monitoring of 
anticonvulsant blood level was conducted as indicated. 
Median hospital stay was recorded and the first 
postoperative control was performed at our hospital 
within the first week after surgery.  
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For ST analysis, recurrence of clinical signs and date 
and cause of death were obtained from the medical 
records, or from the referring veterinarian or client via 
telephone conversation. 
Statistical analyses 
For the purpose of the statistical analyses, dogs were 
classified into two groups depending on the 
histopathological results. Group I included all dogs 
diagnosed with meningiomas and group II included all 
dogs with gliomas.  
Survival time was defined as the time from surgery 
until the date of death. Dogs that died within 7 days of 
surgery from complications directly related to the 
surgical procedure and those with incomplete medical 
records were excluded from the survival analysis. Dogs 
that died of causes unrelated to tumor progression were 
censored. For dogs that were still alive at the time of 
data analysis, the corresponding number of days 
between surgery and time where data was collected was 
considered.  
The Kaplan-Meier product limit method was used to 
calculate median ST by means of a commercially 
available statistical analysis software (Statistical 
Package for the Social Sciences v.20 (SPSS Inc., 
Chicago, IL)(SPSS)). The effect of age, sex, and type 
of tumor (meningioma versus glioma) on ST was 
evaluated.  
Categorical data was evaluated using Fisher's exact test. 
Shapiro-Wilk test confirmed the majority of the 
continuous variables were not normally distributed; 
therefore, a non-parametric test (Kruskal-Wallis) was 
used. In addition, for each MRI study the effects of the 
severity of the midline shift, perilesional edema, and 
ventricular compression on the ST were evaluated. 
Severity of the midline shift and its potential correlation 
with ST was evaluated for each group separately by 
means of Pearson’s correlations. An ANOVA test was 
used to evaluate the association between perilesional 
edema and ST, and the effect of ventricular 
compression on ST was evaluated using a t-test. 
Significance level was set at P value ≤ 0.05. 
Results 
During the study period, SRA was performed on 35 
dogs with intracranial tumors. Four dogs (3 with a 
meningioma and 1 with a glioma) were excluded from 
the study because they died within 7 days following 
surgical resection. Two of them died secondary to 
middle cerebral artery thrombosis occurring 4 and 12 
hours after surgery. Post-mortem examination was 
performed in both cases. The other 2 dogs were 
euthanized due to postoperative aspiration pneumonia, 
and intraoperative hypotension and cardiorespiratory 
failure, respectively. Two additional dogs were 
excluded because of incomplete medical records. 
Therefore, 29 dogs with a histopathologically 
confirmed primary intracranial neoplasia survived >7 
days following surgical resection and were included in 
the study. There were 15 (52%) meningiomas (group I) 
and 14 (48%) gliomas (group II). 
In group I, 6 (40%) dogs were male (4 intact, 2 
neutered) and 9 (60%) were female (3 intact, 6 spayed). 
Median age at initial presentation was 11 years (mean, 
10.3 years; range, 5-14.6 years). Seven dogs were 
purebreds and 8 were mixed breeds. Only German 
shepherd dogs were represented by >1 dog (n=2). In 
Group II, 8 (57%) dogs were male (5 intact, 3 neutered) 
and 6 (43%) were female (1 intact, 5 spayed). Median 
age at initial presentation was 8.8 years (mean, 8.6 
years; range, 6-12.5 years). Eight dogs in group II were 
purebreds and 6 were mixed breeds. Breeds represented 
by >1 dog included Golden Retriever (n=4) and Boxer 
(n=2). Clinical signs reflected the neuroanatomic 
location of the tumor in all dogs. The most common 
clinical signs were seizures and behavioral changes, 
present in 24 of 29 dogs. Contralateral motor and 
sensory deficits were noted in 3 of 29 dogs. Two dogs 
also showed clinical signs consistent with central 
vestibular disease including obtundation, head tilt, 
tetraparesis and spontaneous nystagmus. The duration 
of clinical signs prior to diagnosis varied widely, 
ranging from 1 day to 1 year (mean, 54 days). 
Three types of surgical approaches were used to resect 
the 29 intracranial masses visualized on MRI including 
transfrontal (20 dogs), frontoparietal (5 dogs), and 
parietotemporal (4 dogs) approaches. Median hospital 
stay for all surviving dogs was 3 days (range, 2–6 days). 
All dogs but two had one surgery performed. Two dogs 
with meningiomas underwent more than one surgery. 
One of these two dogs was still alive 2735 days (7.5 
years) after the first surgery, with a total of three 
surgeries performed. A second surgery was performed 
1440 days after first one, and a third surgery 450 days 
after the second surgical procedure. This dog had a 
Grade I psammomatous meningioma, with little 
histopathological change between the first and second 
biopsies. The other dog had a histopathological 
confirmation of transitional meningioma, and died 
1740 days (4.7 years) after the first surgery having had 
a second surgery performed 1224 days after the first 
tumor resection. In addition, two dogs were censored 
because they died from causes unrelated to tumor 
progression. One dog, which had a meningioma, died 
768 days after surgery due to renal failure. One dog 
with an oligodendroglioma died 15 days after surgery 
after developing a pericardial effusion apparently 
unrelated to the tumor. Post-mortem examination was 
performed and no underlying etiology for the 
pericardial effusion was found. 
A board-certified pathologist evaluated all tumors and 
classified them according to the WHO classification 
system (Louis et al., 2007). There were 15 (52%) 
meningiomas and 14 (48%) gliomas.  
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Fig. 2. Grade I canine frontal lobe transitional meningioma. Transverse T2W, T1W and T1W post contrast (T1+C) magnetic 
resonance image at the level of frontal lobe. (A): T2W: The tumor shows hyperintensity respect the grey matter and peritumoral 
edema. (B): T1W: the tumor shows isointensity respect the grey matter. (C): T1W+C: the tumor enhanced homogenously and there 
is also meningeal enhancement.  Also noted the midline shift present in all three sequences. (D): Transverse T1WHematoxylin and 
eosin stain showing whorls of spindle-shaped cells. Original magnification 40x. 
 
 
Fig. 3. Grade III canine frontal lobe oligodendroglioma. Transverse T2W, T1W and T1W post contrast (T1W+C) magnetic 
resonance image at the level of the frontal lobes. (A): T2W: Well-defined T2-hyperintensity lesion respect the grey matter. (B): 
T1W: The lesion shows heterogeneously T1-hypointensity respect the grey matter. (C): T1W+C: Mild enhancement in the medial 
ventral part of the lesion. Also noted the midline shift present in all three sequences. (D): Hematoxylin and eosin stain showing the 
honeycomb pattern characteristic of these tumors. Original magnification 400x. 
 
All tumors had a rostrotentorial location. Meningioma 
subtypes represented included transitional (7), 
psammomatous (1), fibroblastic (1), meningothelial 
(1), atypical (2), and anaplastic (3). According to the 
WHO classification system (Louis et al., 2007), there 
were 10 Grade I meningiomas, 2 Grade II 
meningiomas, and 3 Grade III meningiomas (Fig. 2). 
The gliomas resected included oligodendrogliomas (8), 
astrocytomas (4), and anaplastic gliomas (2). There was 
1 Grade I glioma, 5 Grade II gliomas, and 8 Grade III 
gliomas (Fig. 3).  
Median ST for dogs with meningiomas was 422 days 
(mean, 731 days; range, 10-2735 days). Median ST for 
dogs with gliomas was 66 days (mean, 117 days; range, 
10-730 days). Kaplan-Meier survival analysis indicated 
that ST for dogs with meningiomas treated with SRA 
was statistically longer than ST for dogs with gliomas 
treated with SRA (F= 0.024; P<0.05) (Fig. 4).  
In the meningioma group, 6/15 (40%) had ≥ 20% of 
midline shift displacement, whereas 5/14 (36%) 
gliomas showed this feature. A negative correlation 
between the presence of a midline shift and ST was 
observed for meningiomas (P=0.037). In the 
meningioma group, 14/15 (93%) had ≤10% of edema, 
with only 1 dog meningioma having >10% of edema. 
In the glioma group, 4/14 (28.6%) had >10% of edema, 
9/14 (64.3%) had <10% of edema, and 1/14 (7.1%) had 
no observable edema on MRI. No significant 
association between the presence of peritumoral edema 
and ST was observed for either type of tumor. Ten of 
15 (66.7%) meningiomas had ventricular compression 
in comparison with 9/14 cases (64.3%) in the glioma 
group. A statistically significant negative association 
between the presence of ventricular compression and 
ST was observed for meningiomas (P=0.038). For 
gliomas, there were no significant associations between 
any of the MRI variables and ST. Among all data 
collected, only tumor histopathology (meningioma vs. 
glioma) (Fig. 3), and the presence of a midline shift and 
ventricular compression in meningiomas had a 
significant influence on ST. 
 
 
Fig. 4. Kaplan-Meier survival curve. Median survival times 
in dogs with intracranial primary tumors treated with SRA for 
meningiomas (blue) compared with gliomas (green). 
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Discussion 
The results of the present study suggest that in dogs 
with intracranial rostrotentorial meningiomas, SRA 
might result in ST longer than previously reported. In 
our study, dogs with meningiomas treated with SRA 
had a median ST of 422 days, which compares 
favorably to previously published median ST after 
standard surgical resection, which have typically 
ranged from 180 to 210 days (Kostolich et al., 1987; 
Niebauer et al., 1991; Axlund et al., 2002; Bilderback 
et al., 2006; Rossmeisl, 2014). In addition, we report 
ST for 14 gliomas treated with SRA, with a median 
survival of 66 days, which is slightly longer than 
previously reported with palliative treatment (Adams et 
al., 2005).  Of the secondary changes evaluated on 
MRI, the presence of a midline shift and ventricular 
compression were significantly associated with a lower 
ST in dogs with meningiomas treated with SRA, 
suggesting a negative prognostic implication. For the 
glioma group, we did not observe any associations 
between MRI characteristics and ST. 
All the tumors included in our study had a 
rostrotentorial location, which might have influenced 
the decision to operate as well as the long-term ST. In 
general, rostrontentorial tumors have been reported to 
have a better prognosis than infratentorial neoplasms 
(Dickinson, 2014). Focusing on meningiomas, the 
available literature has reported median ST of 180-210 
days after SRA (Kostolich et al., 1987; Niebauer et al., 
1991; Axlund et al., 2002; Bilderback et al., 2006; 
Rossmeisl, 2014). However, dogs with meningiomas 
treated with SRA in this study achieved a longer 
median ST (median, 422 days; mean, 731 days). 
Similar to previous studies, (Axlund et al., 2002; Klopp 
et al., 2009) dogs that died within 7 days after surgery 
were not included in the ST analyses. However, not all 
previously published studies followed the same criteria, 
making comparisons between studies challenging. 
Most of the reports available described surgical 
resection of olfactory bulb or frontal lobe 
meningiomas, similar to our study. One of the first 
reports describing intracranial surgery in dogs 
(Kostolich et al., 1987) included 4 olfactory 
meningiomas treated with surgery with a median ST of 
135 days, with all dogs surviving beyond the first 7 
days after surgery. The longest median ST described for 
dogs with meningiomas treated with SRA was 210 
days, based on 18 cases (Axlund et al., 2002). This 
report excluded from the survival analyses those dogs 
that died within the first 7 days following surgical 
resection, similar to the method that was followed in the 
present study. The most recent report describing SRA 
for the treatment of canine brain tumors (Bilderback et 
al., 2006) reported a median ST of 201 days. However, 
this study comprised a small number of cases and only 
included 5 meningiomas. Moreover, one of these 5 
dogs died during the third day after surgery. With the 
data available it was difficult to obtain the exact ST for 
the remaining 4 patients, although a median ST of 204 
days was inferred from the data provided. Overall, our 
study achieved a longer median ST for dogs with 
meningiomas surviving >7 days after SRA, in 
comparison to previous studies that used similar criteria 
to calculate ST (Axlund et al., 2002). In our study the 
two cases with meningioma that had more than one 
surgery have had a slightly positive influence in our ST. 
If these animals had been included only for the first 
procedure, the median ST for meningiomas would also 
have been 422 days, with a mean of 611 days. 
History and signalment from the dogs included in this 
study were similar to previous studies, including a 
majority of older dogs, consistent with the previously 
reported average age at presentation of 9.5-11 years 
(Bagley et al., 1999; Axlund et al., 2002; Song et al., 
2013; Dickinson, 2014). Also, both genders appeared 
equally represented, which matches the lack of a sex 
predisposition described in the literature (Dickinson, 
2014). It has been suggested that meningiomas are 
overrepresented in Golden Retrievers, Boxers, and 
Miniature Schnauzers, and that astrocytomas and 
oligodendrogliomas are overrepresented in 
brachycephalic breeds (Dickinson, 2014). In our study, 
we did not observe a clear breed predisposition in the 
meningioma group, but there were 4 gliomas diagnosed 
in Golden Retrievers and 3 in brachycephalic dogs (2 
Boxers, 1 French Bulldog). Seizures were the most 
common initial complaint in our study with 24 of 29 
dogs initially examined for this reason. This is also 
consistent with previous publications (Bagley et al., 
1999; Snyder et al., 2006) and it is not surprising 
considering the rostrontentorial origin of all tumors 
included in the present study. Of the signalment 
variables analyzed in this study (age, sex, and type of 
tumor), only tumor type was found to have a significant 
influence on ST, with meningiomas having longer ST 
than gliomas. 
In humans, meningiomas are histologically categorized 
as Grade I, II, and III according to the 2007 WHO 
classification (Louis et al., 2007). Grade I meningiomas 
include psammomatous, transitional, meningothelial 
and fibroblastic subtypes. Grade II meningiomas 
include atypical and choroid subtypes. Grade III 
meningiomas include anaplastic and papillary subtypes 
and are considered to be the most aggressive (Louis et 
al., 2007). WHO classification of meningiomas in 
domestic animals does not include categorization of 
subtypes into different grades (Koestner et al., 1999) 
therefore, the use of the human classification has been 
suggested (Sturges et al., 2008; Mandara et al., 2009). 
Due to the limited sample size of our study, we were 
unable to evaluate any associations between 
meningiomas subtypes/grades and survival.  
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However, most of the meningiomas included in this 
study were classified as Grade I, which could have 
positively impacted median ST, since Grade I 
meningiomas are typically considered “benign” 
(Sturges et al., 2008). Ideally, future larger studies 
would investigate a potential relationship between 
meningioma subtype/grade and ST, which might add 
useful information for prognostic purposes.  
The recurrence rate of intracranial meningiomas in 
humans is 9-12% with grossly complete excision and 
may be as high as 40% with incomplete excision 
(Spagnuolo et al., 2003) Meningioma recurrence 
depends on extension of resection, location and 
histological grade of the tumor (Schiffer et al., 2005). 
In our study, the main cause of death was the 
progression of neurological signs, behavioral changes, 
and uncontrolled seizures, allegedly related to tumor re-
growth, scar tissue formation or brain herniation trough 
craniectomy defect. In most cases a follow-up MRI to 
confirm tumor recurrence could not be performed, but 
the clinical signs and the neurological exam suggested 
recurrence. Hence, euthanasia due to suspected 
progression of clinical signs was the most common 
cause of death in our patients.  
Fewer studies document ST for canine gliomas. In 
humans, gliomas are categorized as Grade I, II, III, and 
IV according to their histopathologic features and the 
2007 WHO classification system, with Grade IV 
gliomas being the most aggressive type (Louis et al., 
2007).  
Grade I include: subependymal giant cell astrocytoma 
and pilocytic astrocytoma. Grade II include: 
pilomyxoid astrocytoma, diffuse astrocytoma, 
pleomorphic xanthoastrocytoma, oligodendroglioma 
and oligoastrocytoma. Grade III include: anaplastic 
astrocytoma, anaplastic oligodendroglioma and 
anaplastic oligoastrocytoma. Grade IV, the most 
aggressive type, include:  glioblastoma, giant cell 
glioblastoma and gliosarcoma (Louis et al., 2007).  
To the authors’ knowledge, this is the first study 
reporting ST in canine gliomas treated with SRA 
showing a median ST of 66 days (mean 117 days). 
Interestingly, one dog with an anaplastic glioma 
survived for 2 years after surgery before dying of 
uncontrolled seizures.  
In human medicine, it has been suggested that repeated 
surgery with maximal extend of resection should be 
standard of care for recurrent low-grade gliomas 
(Uppstrom et al., 2016).  
In the present study, ST for gliomas appeared slightly 
longer than the ST that had been previously reported 
following palliative care (Adams et al., 2005), but 
considerably shorter than the ST previously reported 
following radiotherapy or following surgery and 
radiotherapy (Adams et al., 2005). Furthermore, this 
type of surgery allows the possibility of a 
histopathological confirmation and the use of 
alternatives or adjunctive future therapies, such as 
radiation therapy or chemotherapy. 
There are important factors to consider when 
comparing the results of ST for meningiomas and 
gliomas. The different nature and growth patterns of 
both types of tumors (extra- versus intra-axial) is the 
most likely factor influencing the differences in ST 
observed after SRA. Gliomas, being intra-axial tumors, 
may be more difficult to access because they often have 
deeper locations than meningiomas; moreover, gliomas 
may also be more challenging to resect because they 
typically lack a clear plane of dissection (Niebauer et 
al., 1991; Rossmeisl, 2014). Another important factor 
to consider is that most meningiomas included in this 
study were Grade I, whereas most gliomas were Grade 
III. Therefore, it is likely that in the present study 
meningiomas showed a less aggressive biological 
behavior than gliomas.  
Regarding the MRI secondary changes evaluated in this 
study (midline shift, ventricular compression and 
peritumoral edema), there was a correlation between 
the presence of a midline shift and ventricular 
compression and ST for meningiomas. A study 
investigated the MRI characteristics of histological 
confirmed meningiomas and concluded that it was not 
possible to predict the meningioma subtype or grade 
based on MRI features, emphasizing the need for 
histopathology for an antemortem diagnostic 
confirmation (Sturges et al., 2008). Another study 
evaluated potential prognostic factors associated with 
ST in brain tumors and found no significant correlation 
between the edema observed on MRI and ST, 
(Rossmeisl et al., 2013) which was also observed in the 
present study. 
At our institution, radiation therapy is always 
recommended following surgical resection of 
intracranial tumors; however, radiotherapy was not 
available in our country during the study period, and 
owners elected to not pursue this treatment modality 
due to the logistic difficulties and the expenses that 
would be associated with pursuing radiotherapy in a 
different country. 
There were several limitations and strengths to our 
study. Limitations included the retrospective nature of 
the study, along with a limited sample size. As in all 
retrospective studies, multiple variables existed that 
could not be controlled, which might have influenced 
our results. At the time of the surgery, information 
regarding whether the excision was considered to be 
complete or incomplete was not included in the medical 
records. Thus, it was not possible to correlate if the 
completeness or not of the surgical resection might 
have had an influence on recurrence or ST. Euthanasia 
due to recurrence or progression of clinical signs was 
the most common cause of death. In most of these 
http://www.openveterinaryjournal.com 
A. Suñol et al.  Open Veterinary Journal, (2017), Vol. 7(4): 375-383 
________________________________________________________________________________________________________ 
 
382 
cases, tumor recurrence was suspected, but a repeat 
MRI or a postmortem histopathological examination 
were not performed, which is another limitation of the 
study.  
Our decision to exclude the patients that did not survive 
pass >7 days after surgery was intended to eliminate the 
direct influence of postsurgical complications on the 
ST, as well as to be able to compare the results with 
previously published studies that calculated ST 
following the same approach (Axlund et al., 2002).  
One of the strengths of this study is that all biopsies 
were obtained during the initial surgical resection. 
Other previous clinical studies, in particular during the 
treatment of gliomas, rely on suspected gliomas by 
MRI characteristics or biopsy or postmortem samples 
obtained following radiation or chemotherapy, which 
might change the nature or histopathological grade of 
those tumors (Brearley et al., 1999; Spugnini et al., 
2000; Adams et al., 2005).  
Moreover, radiation therapy itself has been reported to 
induce the formation of brain tumors in people ( Salvati 
et al., 2003; Umansky et al., 2008; Ecemis et al., 2013) 
and dogs (Luján Feliu-Pascual et al., 2009).  
Our study also provides ST data after SRA for a group 
of 14 dogs with gliomas. There is very limited 
information available on ST after SRA for 
histopathologically confirmed canine gliomas. As such, 
the results from the present study add extra data to the 
scant information currently available, and provide 
additional evidence that neurologists can use when 
choosing treatment options for presumptive glial 
tumors. 
The results of this study suggest that SRA might be an 
appropriate treatment, particularly for meningiomas, 
when radiation therapy is not readily available. Also, 
the presence of midline shift and ventricular 
compression might be negative prognostic factors for 
dogs with meningiomas.  
For canine gliomas, this is the first clinical study 
reporting ST using SRA. Results shows longer survival 
time with surgery compared to previously reported 
palliative treatment for glioma. Also, no MRI 
characteristics appeared to be associated with ST in this 
group of dogs with gliomas.  
Studies that investigate the ST associated with the 
different therapies available to treat brain tumors, such 
as the one presented here, provide veterinary 
neurologists with additional evidence to aid in the 
decision-making process and to estimate the most likely 
prognosis for each one of these patients. 
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